Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

Abbott (ABT) is positioned as the steadier cash-flow story—FY2025 revenue of $44.3B (+~5.5%), net income ~ $6.5B and free cash flow ~ $7.4B—after adding oncology via Exact Sciences for $23B, but with net margin falling to 14.7% from 31.9% and some pressure in FreeStyle Libre and Nutrition. Glaukos (GKOS) is the faster-growth, higher-burn setup—FY2025 revenue $507.4M (+32%) but net loss ~ $187.7M and negative free cash flow (~$22.5M)—with iDose growth expected and new product Epioxa targeting >$1B revenue potential by 2030. Overall, the article frames both names as attractive in different ways, with mixed fundamentals (profitability/margins vs. growth) and meaningful execution/regulatory and single-site supply risks.

Analysis

ABT is the steadier compounding vehicle, but the market will likely pay for it only if the acquired diagnostics asset can lift growth without a prolonged margin reset. The second-order issue is that a larger diagnostics footprint makes ABT more exposed to reimbursement, coding, and payer utilization cycles than its historical mix; that can compress the premium multiple if integration costs linger or if nutrition/pricing pressure persists. In the near term, the stock should trade more on margin cadence and debt tolerance than on headline revenue.

GKOS is the cleaner operating-leverage story, but it is also a more fragile one: surgeon adoption plus reimbursement creates a narrow funnel where one policy or coding change can derail growth for multiple quarters. The hidden risk is not competition alone; it is that larger ophthalmology platforms can outspend on promotion and distribution while GKOS still bears manufacturing concentration risk and a U.S.-heavy mix. That makes the next 1-3 months about reimbursement/read-through, while the 6-18 month debate is whether Epioxa becomes a durable franchise or just another niche launch.

Contrarian view: the market may be over-penalizing ABT for being ‘boring’ while underestimating how much optionality a diversified balance sheet has if diagnostics and medtech cross-sell works. Conversely, it may be overpaying for GKOS growth if the path to scale depends on external payment decisions more than controllable execution. The clean falsifier for the GKOS bull case is any sign of slower iDose/Epioxa uptake or reimbursement friction; for ABT, it is another quarter of margin erosion without evidence the acquired growth engine is accretive.

Key Decisions for Investors

• Hold a modest long ABT position vs. XLV for 6-12 months only if management can show post-deal margin stabilization; cut if operating margin keeps trending down or if debt metrics deteriorate.
• Avoid chasing GKOS after strength; prefer buying a 3-6 month pullback only if reimbursement commentary stays constructive and channel checks confirm surgeon adoption.
• Pair trade idea: long ABT / short ALC as a lower-beta way to express that scaled diversified healthcare should outperform single-category ophthalmology if reimbursement tightens.
• Set a watch alert on GKOS for any payer or Medicare coding change; if that hits, the stock can re-rate lower quickly and the downside is likely larger than the market currently implies.
• If ABT guidance is reaffirmed while integration costs fade, consider adding on weakness; if the market starts rewarding profitability over growth, ABT should outperform high-multiple medtech names on a 6-18 month basis.